AKT1 and allergic rhinitis: Bicalutamide, a non-steroidal androgen receptor antagonist, demonstrated a therapeutic role in allergic rhinitis in an animal model, further our results indicated activation of PI3K–PKB cascade was significantly blocked by Bicalutamide, which can shown as a new direction on clinical drug prevention and treatment of allergic rhinitis.